About This Fund
Forbion Growth Fund III is a late-stage life sciences growth fund managed by Forbion, a specialist European venture capital firm headquartered in Naarden, the Netherlands, with offices in Munich, Germany and Boston, United States. The fund targets later-stage biopharmaceutical companies developing novel therapies in areas of high medical need, focusing on European and North American clinical-stage assets with significant near-term catalysts.
The fund is part of Forbion's Growth strategy, which provides private growth capital to clinical-stage biopharma companies, crossover financing to companies preparing for public listings, and opportunistic capital to undervalued public biopharmaceutical companies. Forbion typically leads investment rounds and secures board representation to support portfolio companies through key clinical and regulatory milestones. Therapeutic areas of focus include oncology, rare diseases, immunology, and cardiovascular and metabolic conditions.
Forbion has built a substantial track record in European life sciences growth equity, with total assets under management exceeding €5 billion following the close of its latest fund vehicles. The Growth franchise, of which this fund is a part, has backed European biopharma companies including Gyroscope Therapeutics (acquired by Novartis), and has attracted institutional investors spanning Dutch pension advisors, global asset managers, pharma strategic investors, and international fund-of-funds. Forbion's in-house scientific expertise and deep European academic network underpin its ability to identify and support best-in-class clinical-stage therapeutic assets.